Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metoprolol and Trimetazidine for Coronary Heart Disease With Angina
NCT07074834Completed
- Sponsor
- Renmin Hospital, Hubei University of Medicine
- Start
- Feb 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of trimetazidine in coronary heart disease (CHD) and angina pectoris (2 arms), sponsored by Renmin Hospital, Hubei University of Medicine. Primary endpoints: Change in Clinical Efficacy Rate at 3 months, Change in Frequency of Angina Attacks at 3 months and 1 more. Started Feb 2021; status: completed.
02
Drugs
trimetazidine
03
Conditions
coronary heart disease (CHD)angina pectoris
Beyond the preview
Go deeper on NCT07074834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074834.